Following the introduction of PSA screening, the prostate cancer age-standardized incidence rate among men aged 50–74 increased 1.8% annually until 2007 (p = 0.006) before declining at an annualized rate of −5.9% (p = 0.005) until 2014. The gene discussed is KLK3; the disease is prostate cancer.